Insights into the Global Pharmacogenomics Market: Exploring Regional Trends

Market Overview:

The Pharmacogenomics Market is rapidly expanding globally, revolutionizing the field of personalized medicine and drug development by integrating genomic information into clinical practice. Japan Pharmacogenomics Market: In Japan, the Pharmacogenomics Market is witnessing significant growth, driven by advancements in healthcare technology and a growing emphasis on personalized medicine. Japanese pharmaceutical companies are at the forefront of integrating pharmacogenomics into drug development and clinical practice, aiming to improve treatment outcomes and reduce adverse drug reactions. Moreover, government initiatives to promote precision medicine and genomic research are fueling market expansion in the country.

China Pharmacogenomics Market: China's Pharmacogenomics Market is experiencing rapid growth, propelled by investments in biotechnology and healthcare infrastructure. The market is characterized by a focus on genetic testing and personalized treatment approaches, driven by increasing healthcare expenditures and a large patient population. Domestic companies are leveraging advancements in genomic technology to develop innovative pharmacogenomic solutions tailored to the Chinese population's diverse genetic makeup. USA Pharmacogenomics Market: The United States dominates the global Pharmacogenomics Market, with a robust healthcare ecosystem and significant research and development investments. American companies lead in the development and commercialization of pharmacogenomic tests and precision medicine solutions. The market is driven by factors such as the increasing prevalence of chronic diseases, advancements in genomic research, and the adoption of personalized medicine approaches by healthcare providers.

India Pharmacogenomics Market: India's Pharmacogenomics Market is witnessing steady growth, fueled by advancements in healthcare infrastructure and increasing awareness about personalized medicine. The market is characterized by a growing demand for genetic testing services and pharmacogenomic solutions to optimize drug therapy and improve patient outcomes. Indian pharmaceutical companies are investing in research and development initiatives to develop pharmacogenomic tests tailored to the Indian population's genetic diversity. Australia Pharmacogenomics Market: The Pharmacogenomics Market in Australia is characterized by a focus on precision medicine and personalized treatment approaches. With a strong emphasis on genomic research and healthcare innovation, Australian companies are developing pharmacogenomic tests and solutions to optimize drug therapy and enhance patient care. Moreover, government support for genomic research and healthcare initiatives contributes to market growth and technology adoption in Australia.

South Korea Pharmacogenomics Market: South Korea's Pharmacogenomics Market is experiencing steady growth, driven by advancements in genomic research and healthcare technology. Korean companies are investing in the development of pharmacogenomic tests and precision medicine solutions to address the evolving needs of patients and healthcare providers. The market is characterized by collaborations between industry stakeholders, academia, and government bodies to promote genomic research and technology innovation.

Germany Pharmacogenomics Market: Germany stands at the forefront of pharmacogenomics innovation in Europe, with a strong emphasis on precision medicine and personalized treatment approaches. German companies lead in the development and commercialization of pharmacogenomic tests and precision medicine solutions, aiming to improve drug efficacy and safety. The market is characterized by collaborations between industry leaders, research institutions, and healthcare providers to drive genomic research and technology adoption. United Kingdom Pharmacogenomics Market: The United Kingdom's Pharmacogenomics Market reflects a commitment to delivering personalized medicine and precision healthcare solutions. With a focus on genomic research and healthcare innovation, British companies are developing pharmacogenomic tests and precision medicine approaches to optimize drug therapy and improve patient outcomes. Moreover, government funding and regulatory support foster a conducive environment for genomic research and technology adoption in the UK.

In conclusion, the global Pharmacogenomics Market offers diverse opportunities and challenges across different regions, driven by factors such as healthcare infrastructure, genomic research, and regulatory frameworks. Understanding regional dynamics is crucial for stakeholders to navigate the market effectively and leverage opportunities for innovation and growth in personalized medicine.

 

Pharmacogenomics Market Industry Trends, Major Competitors, Business Strategies And Global Development

Market Overview

According to Market Research Future (MRFR), the Global Pharmacogenomics Market Size is Projected to grow at a CAGR of 8.52% Over the Forecast Period 2023-2032.

Pharmacogenomics, a rapidly advancing field at the intersection of genetics and pharmacology, is revolutionizing drug development and personalized medicine. At its core lies the study of drug response genetics, which involves understanding how an individual's genetic makeup influences their response to medications. This intricate interplay between genes and drug metabolism is reshaping the pharmaceutical landscape by enabling the creation of tailored treatments that optimize efficacy while minimizing adverse reactions.

The Pharmacogenomics market is experiencing unprecedented growth as stakeholders across healthcare and pharmaceutical sectors recognize its potential to enhance patient outcomes and streamline drug development processes. By leveraging insights from drug response genetics, researchers and clinicians can predict how patients will respond to specific medications, allowing for the customization of treatment regimens based on individual genetic profiles. This precision medicine approach not only improves patient safety and efficacy but also contributes to cost savings by reducing instances of trial-and-error prescribing and adverse drug events. As the understanding of drug response genetics deepens and genomic technologies become more accessible, the Pharmacogenomics market is poised for continued expansion, promising a future where medications are tailored to each patient's unique genetic blueprint, ushering in a new era of personalized healthcare.

Market Opportunities

Pharmacogenomics is considered to be a vital aspect in terms of cancer treatment, having proved to be a favorable option helping with the survival of patients. Over and above that, pharmacogenomics also has managed to reduce the additional cost owing to unresponsive treatment. Therefore, growing use of pharmacogenomics for the treatment of cancer has resulted in numerous significant discoveries, which is bound to contribute to the growth of the worldwide market in the upcoming period.

Key players

The top pharmacogenomics companies include Assurex Health Inc. (U.S.), Pathway Genomics (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Myriad Genetics, Inc. (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), GeneTech (U.S.), 23andMe, Inc. (U.S.), and others.

Market Segmentation

The global pharmacogenomics market has been segmented on the basis of technology, application, and end user.

The types of technology in the market include microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is further segmented on the basis of Sanger sequencing, pyrosequencing, next-generation sequencing, and others.

The segments based on application are oncology, cardiology, neurological disorders, and others. The oncology segment can be considered for breast cancer, lung cancer, and others.

On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others.

Regional Insight

The pharmacogenomics market is spread across the primary regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has been identified as the dominant region in the global pharmacogenomics market, on account of highly-developed healthcare industry coupled with the inclusion of developed countries such as the United States (U.S.) as well as Canada. Furthermore, the expansion of the patient pool suffering from cardiovascular diseases as well as the growing healthcare expenditure is nurturing the growth of the regional market. As per the Centers for Diseases Control and Prevention, in 2015, heart disease had been the main cause of death for men as well as women in the U.S. In addition, the analysis suggested that the spending on healthcare for heart diseases in the country touches the valuation of USD 200 billion every year.

Data analysts concur that Europe stands second in the global pharmacogenomics market, with the Asia Pacific following suit. The surge in the funds for research and development on top of the increasing government support and the expanding patient population will prove to be instrumental in the market growth. Plus, the region also benefits from the primary contribution of the developed nations such as France and Germany with excellent growth prospects in the medical field.

Racing ahead at the fastest growth rate is the region of Asia Pacific, with the primary reasons being the burgeoning patient pool and the progressively growing economies such as India and China in the region. The Indian Brand Equity Foundation had reported in 2016 that the biotech industry in India is expected to arrive at the valuation of USD 100 billion by the year 2025, crossing the value of USD 7 billion it had reached in 2015. The industry is also expected to expand at a growth rate of 30.46% in the mentioned evaluation period, as per reports.

Meanwhile, the growth of the Middle East & Africa market has been inferior to other regions in the global pharmacogenomics market. This stunted growth can be the result of the poor economy, low expenditure on healthcare, and the rigid government policies, particularly in Africa. Concurrently, the substantial portion of the regional market is controlled by the Middle East, with the backing from the well-established healthcare industry combined with the growing healthcare expenditure. Apart from this, developed countries such as Dubai, Saudi Arabia, and Qatar have a big hand in the growth of the Middle East & Africa market.

Related reports-

Bioprocess Technology

North America Microarray

Paronychia treatment

Bladder Cancer

Wound Closure Devices

For more information, Please Visit us @ Market Research Future

Pharmacogenomics Market Size, Share Business Outlook, Growth Opportunities, Trends and Forecasts

Market Overview

According to Market Research Future (MRFR), the Global Pharmacogenomics Market Size is Projected to grow at a CAGR of 8.52% Over the Forecast Period 2023-2032.

Pharmacogenomics, a rapidly advancing field at the intersection of genetics and pharmacology, is revolutionizing drug development and personalized medicine. At its core lies the study of drug response genetics, which involves understanding how an individual's genetic makeup influences their response to medications. This intricate interplay between genes and drug metabolism is reshaping the pharmaceutical landscape by enabling the creation of tailored treatments that optimize efficacy while minimizing adverse reactions.

The Pharmacogenomics market is experiencing unprecedented growth as stakeholders across healthcare and pharmaceutical sectors recognize its potential to enhance patient outcomes and streamline drug development processes. By leveraging insights from drug response genetics, researchers and clinicians can predict how patients will respond to specific medications, allowing for the customization of treatment regimens based on individual genetic profiles. This precision medicine approach not only improves patient safety and efficacy but also contributes to cost savings by reducing instances of trial-and-error prescribing and adverse drug events. As the understanding of drug response genetics deepens and genomic technologies become more accessible, the Pharmacogenomics market is poised for continued expansion, promising a future where medications are tailored to each patient's unique genetic blueprint, ushering in a new era of personalized healthcare.

Market Opportunities

Pharmacogenomics is considered to be a vital aspect in terms of cancer treatment, having proved to be a favorable option helping with the survival of patients. Over and above that, pharmacogenomics also has managed to reduce the additional cost owing to unresponsive treatment. Therefore, growing use of pharmacogenomics for the treatment of cancer has resulted in numerous significant discoveries, which is bound to contribute to the growth of the worldwide market in the upcoming period.

Key players

The top pharmacogenomics companies include Assurex Health Inc. (U.S.), Pathway Genomics (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Myriad Genetics, Inc. (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), GeneTech (U.S.), 23andMe, Inc. (U.S.), and others.

Market Segmentation

The global pharmacogenomics market has been segmented on the basis of technology, application, and end user.

The types of technology in the market include microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is further segmented on the basis of Sanger sequencing, pyrosequencing, next-generation sequencing, and others.

The segments based on application are oncology, cardiology, neurological disorders, and others. The oncology segment can be considered for breast cancer, lung cancer, and others.

On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others.

Regional Insight

The pharmacogenomics market is spread across the primary regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has been identified as the dominant region in the global pharmacogenomics market, on account of highly-developed healthcare industry coupled with the inclusion of developed countries such as the United States (U.S.) as well as Canada. Furthermore, the expansion of the patient pool suffering from cardiovascular diseases as well as the growing healthcare expenditure is nurturing the growth of the regional market. As per the Centers for Diseases Control and Prevention, in 2015, heart disease had been the main cause of death for men as well as women in the U.S. In addition, the analysis suggested that the spending on healthcare for heart diseases in the country touches the valuation of USD 200 billion every year.

Data analysts concur that Europe stands second in the global pharmacogenomics market, with the Asia Pacific following suit. The surge in the funds for research and development on top of the increasing government support and the expanding patient population will prove to be instrumental in the market growth. Plus, the region also benefits from the primary contribution of the developed nations such as France and Germany with excellent growth prospects in the medical field.

Racing ahead at the fastest growth rate is the region of Asia Pacific, with the primary reasons being the burgeoning patient pool and the progressively growing economies such as India and China in the region. The Indian Brand Equity Foundation had reported in 2016 that the biotech industry in India is expected to arrive at the valuation of USD 100 billion by the year 2025, crossing the value of USD 7 billion it had reached in 2015. The industry is also expected to expand at a growth rate of 30.46% in the mentioned evaluation period, as per reports.

Meanwhile, the growth of the Middle East & Africa market has been inferior to other regions in the global pharmacogenomics market. This stunted growth can be the result of the poor economy, low expenditure on healthcare, and the rigid government policies, particularly in Africa. Concurrently, the substantial portion of the regional market is controlled by the Middle East, with the backing from the well-established healthcare industry combined with the growing healthcare expenditure. Apart from this, developed countries such as Dubai, Saudi Arabia, and Qatar have a big hand in the growth of the Middle East & Africa market.

Related reports-

Bioprocess Technology

North America Microarray

Paronychia treatment

Bladder Cancer

Wound Closure Devices

For more information, Please Visit us @ Market Research Future

Pharmacogenomics Market to Observe Impressive Growth During the Forecast Period | Key Companies

Market Overview

According to Market Research Future (MRFR), the Global Pharmacogenomics Market Size is Projected to grow at a CAGR of 8.52% Over the Forecast Period 2023-2032.

Pharmacogenomics, a rapidly advancing field at the intersection of genetics and pharmacology, is revolutionizing drug development and personalized medicine. At its core lies the study of drug response genetics, which involves understanding how an individual's genetic makeup influences their response to medications. This intricate interplay between genes and drug metabolism is reshaping the pharmaceutical landscape by enabling the creation of tailored treatments that optimize efficacy while minimizing adverse reactions.

The Pharmacogenomics market is experiencing unprecedented growth as stakeholders across healthcare and pharmaceutical sectors recognize its potential to enhance patient outcomes and streamline drug development processes. By leveraging insights from drug response genetics, researchers and clinicians can predict how patients will respond to specific medications, allowing for the customization of treatment regimens based on individual genetic profiles. This precision medicine approach not only improves patient safety and efficacy but also contributes to cost savings by reducing instances of trial-and-error prescribing and adverse drug events. As the understanding of drug response genetics deepens and genomic technologies become more accessible, the Pharmacogenomics market is poised for continued expansion, promising a future where medications are tailored to each patient's unique genetic blueprint, ushering in a new era of personalized healthcare.

Market Opportunities

Pharmacogenomics is considered to be a vital aspect in terms of cancer treatment, having proved to be a favorable option helping with the survival of patients. Over and above that, pharmacogenomics also has managed to reduce the additional cost owing to unresponsive treatment. Therefore, growing use of pharmacogenomics for the treatment of cancer has resulted in numerous significant discoveries, which is bound to contribute to the growth of the worldwide market in the upcoming period.

Key players

The top pharmacogenomics companies include Assurex Health Inc. (U.S.), Pathway Genomics (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Myriad Genetics, Inc. (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), GeneTech (U.S.), 23andMe, Inc. (U.S.), and others.

Market Segmentation

The global pharmacogenomics market has been segmented on the basis of technology, application, and end user.

The types of technology in the market include microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is further segmented on the basis of Sanger sequencing, pyrosequencing, next-generation sequencing, and others.

The segments based on application are oncology, cardiology, neurological disorders, and others. The oncology segment can be considered for breast cancer, lung cancer, and others.

On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others.

Regional Insight

The pharmacogenomics market is spread across the primary regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has been identified as the dominant region in the global pharmacogenomics market, on account of highly-developed healthcare industry coupled with the inclusion of developed countries such as the United States (U.S.) as well as Canada. Furthermore, the expansion of the patient pool suffering from cardiovascular diseases as well as the growing healthcare expenditure is nurturing the growth of the regional market. As per the Centers for Diseases Control and Prevention, in 2015, heart disease had been the main cause of death for men as well as women in the U.S. In addition, the analysis suggested that the spending on healthcare for heart diseases in the country touches the valuation of USD 200 billion every year.

Data analysts concur that Europe stands second in the global pharmacogenomics market, with the Asia Pacific following suit. The surge in the funds for research and development on top of the increasing government support and the expanding patient population will prove to be instrumental in the market growth. Plus, the region also benefits from the primary contribution of the developed nations such as France and Germany with excellent growth prospects in the medical field.

Racing ahead at the fastest growth rate is the region of Asia Pacific, with the primary reasons being the burgeoning patient pool and the progressively growing economies such as India and China in the region. The Indian Brand Equity Foundation had reported in 2016 that the biotech industry in India is expected to arrive at the valuation of USD 100 billion by the year 2025, crossing the value of USD 7 billion it had reached in 2015. The industry is also expected to expand at a growth rate of 30.46% in the mentioned evaluation period, as per reports.

Meanwhile, the growth of the Middle East & Africa market has been inferior to other regions in the global pharmacogenomics market. This stunted growth can be the result of the poor economy, low expenditure on healthcare, and the rigid government policies, particularly in Africa. Concurrently, the substantial portion of the regional market is controlled by the Middle East, with the backing from the well-established healthcare industry combined with the growing healthcare expenditure. Apart from this, developed countries such as Dubai, Saudi Arabia, and Qatar have a big hand in the growth of the Middle East & Africa market.

Related reports-

Bioprocess Technology

North America Microarray

Paronychia treatment

Bladder Cancer

Wound Closure Devices

For more information, Please Visit us @ Market Research Future

Pharmacogenomics Market Share, Leading Players and Demand Forecast Report 2032

 

Market Overview

According to Market Research Future (MRFR), the Global Pharmacogenomics Market Share is Projected grow at a CAGR of 8.52% Over the Forecast Period 2023-2032.

Market Drivers and Top Barriers

The deciding factors in the pharmacogenomics market growth include the surging expenditure in research and development (R&D) along with the elevating rate of adverse reactions. World over, there has been a rising focus on precision medicine coupled with the growing need for drug safety as well as efficacy, which has led to the market expansion in recent years. On that note, the strong focus on precision medicine is striving to expand the pharmacogenomics market, as the primary aim of precision medicine is integrating genetic as well as environmental information of certain diseases along with their responses to specific treatments.

This factor helps in targeted drug therapies, in addition to the growing adoption of treatment procedures that reduce the side effects and achieve accurate results, which makes extensive use of pharmacogenomics. For instance, in 2015, the United States (U.S.) government had implemented a new precision medicine initiative to augment the development of individualized care, which includes genetic variability for a variety of chronic disorders.

Additionally, the rapid growth in the number of research studies associated with sequencing, particularly next-generation sequencing, will raise the demand for pharmacogenomic tests in the years to come. This factor will play an integral role in market growth to a large extent.

Top Vendors

Pharmacogenomics market players include Assurex Health Inc. (U.S.), Pathway Genomics (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Myriad Genetics, Inc. (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), GeneTech (U.S.), 23andMe, Inc. (U.S.), and others.

Market Opportunities

Pharmacogenomics is considered to be a vital aspect in terms of cancer treatment, having proved to be a favorable option helping with the survival of patients. Over and above that, pharmacogenomics also has managed to reduce the additional cost owing to unresponsive treatment. Therefore, growing use of pharmacogenomics for the treatment of cancer has resulted in numerous significant discoveries, which is bound to contribute to the growth of the worldwide market in the upcoming period.

Market Segmentation

The global pharmacogenomics market outlook has been segmented on the basis of technology, application, and end user.

The types of technology in the market include microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is further segmented on the basis of Sanger sequencing, pyrosequencing, next-generation sequencing, and others.

The segments based on application are oncology, cardiology, neurological disorders, and others. The oncology segment can be considered for breast cancer, lung cancer, and others.

On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others.

Regional Insight

The pharmacogenomics market is spread across the primary regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has been identified as the dominant region in the global pharmacogenomics market insights, on account of highly-developed healthcare industry coupled with the inclusion of developed countries such as the United States (U.S.) as well as Canada. Furthermore, the expansion of the patient pool suffering from cardiovascular diseases as well as the growing healthcare expenditure is nurturing the growth of the regional market. As per the Centers for Diseases Control and Prevention, in 2015, heart disease had been the main cause of death for men as well as women in the U.S. In addition, the analysis suggested that the spending on healthcare for heart diseases in the country touches the valuation of USD 200 billion every year.

Data analysts concur that Europe stands second in the global pharmacogenomics market, with the Asia Pacific following suit. The surge in the funds for research and development on top of the increasing government support and the expanding patient population will prove to be instrumental in the market growth. Plus, the region also benefits from the primary contribution of the developed nations such as France and Germany with excellent growth prospects in the medical field.

Racing ahead at the fastest growth rate is the region of Asia Pacific, with the primary reasons being the burgeoning patient pool and the progressively growing economies such as India and China in the region. The Indian Brand Equity Foundation had reported in 2016 that the biotech industry in India is expected to arrive at the valuation of USD 100 billion by the year 2025, crossing the value of USD 7 billion it had reached in 2015. The industry is also expected to expand at a growth rate of 30.46% in the mentioned evaluation period, as per reports.

Meanwhile, the growth of the Middle East & Africa market has been inferior to other regions in the global pharmacogenomics market. This stunted growth can be the result of the poor economy, low expenditure on healthcare, and the rigid government policies, particularly in Africa. Concurrently, the substantial portion of the regional market is controlled by the Middle East, with the backing from the well-established healthcare industry combined with the growing healthcare expenditure. Apart from this, developed countries such as Dubai, Saudi Arabia, and Qatar have a big hand in the growth of the Middle East & Africa market.

 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

 

Pharmacogenomics Market Insights To Witness Notable Growth During the Forecast Period 2023-2032

 

Market Overview

According to Market Research Future (MRFR), the Global Pharmacogenomics Market Size is Projected to grow at a CAGR of 8.52% Over the Forecast Period 2023-2032.

Market Drivers and Top Barriers

The deciding factors in the pharmacogenomics market growth include the surging expenditure in research and development (R&D) along with the elevating rate of adverse reactions. World over, there has been a rising focus on precision medicine coupled with the growing need for drug safety as well as efficacy, which has led to the market expansion in recent years. On that note, the strong focus on precision medicine is striving to expand the pharmacogenomics market, as the primary aim of precision medicine is integrating genetic as well as environmental information of certain diseases along with their responses to specific treatments.

This factor helps in targeted drug therapies, in addition to the growing adoption of treatment procedures that reduce the side effects and achieve accurate results, which makes extensive use of pharmacogenomics. For instance, in 2015, the United States (U.S.) government had implemented a new precision medicine initiative to augment the development of individualized care, which includes genetic variability for a variety of chronic disorders.

Additionally, the rapid growth in the number of research studies associated with sequencing, particularly next-generation sequencing, will raise the demand for pharmacogenomic tests in the years to come. This factor will play an integral role in market growth to a large extent.

Top Vendors

Pharmacogenomics market players include Assurex Health Inc. (U.S.), Pathway Genomics (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Myriad Genetics, Inc. (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), GeneTech (U.S.), 23andMe, Inc. (U.S.), and others.

Market Opportunities

Pharmacogenomics is considered to be a vital aspect in terms of cancer treatment, having proved to be a favorable option helping with the survival of patients. Over and above that, pharmacogenomics also has managed to reduce the additional cost owing to unresponsive treatment. Therefore, growing use of pharmacogenomics for the treatment of cancer has resulted in numerous significant discoveries, which is bound to contribute to the growth of the worldwide market in the upcoming period.

Market Segmentation

The global pharmacogenomics market has been segmented on the basis of technology, application, and end user.

The types of technology in the market include microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is further segmented on the basis of Sanger sequencing, pyrosequencing, next-generation sequencing, and others.

The segments based on application are oncology, cardiology, neurological disorders, and others. The oncology segment can be considered for breast cancer, lung cancer, and others.

On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others.

Regional Insight

The pharmacogenomics market is spread across the primary regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has been identified as the dominant region in the global pharmacogenomics market insights, on account of highly-developed healthcare industry coupled with the inclusion of developed countries such as the United States (U.S.) as well as Canada. Furthermore, the expansion of the patient pool suffering from cardiovascular diseases as well as the growing healthcare expenditure is nurturing the growth of the regional market. As per the Centers for Diseases Control and Prevention, in 2015, heart disease had been the main cause of death for men as well as women in the U.S. In addition, the analysis suggested that the spending on healthcare for heart diseases in the country touches the valuation of USD 200 billion every year.

Data analysts concur that Europe stands second in the global pharmacogenomics market, with the Asia Pacific following suit. The surge in the funds for research and development on top of the increasing government support and the expanding patient population will prove to be instrumental in the market growth. Plus, the region also benefits from the primary contribution of the developed nations such as France and Germany with excellent growth prospects in the medical field.

Racing ahead at the fastest growth rate is the region of Asia Pacific, with the primary reasons being the burgeoning patient pool and the progressively growing economies such as India and China in the region. The Indian Brand Equity Foundation had reported in 2016 that the biotech industry in India is expected to arrive at the valuation of USD 100 billion by the year 2025, crossing the value of USD 7 billion it had reached in 2015. The industry is also expected to expand at a growth rate of 30.46% in the mentioned evaluation period, as per reports.

Meanwhile, the growth of the Middle East & Africa market has been inferior to other regions in the global pharmacogenomics market. This stunted growth can be the result of the poor economy, low expenditure on healthcare, and the rigid government policies, particularly in Africa. Concurrently, the substantial portion of the regional market is controlled by the Middle East, with the backing from the well-established healthcare industry combined with the growing healthcare expenditure. Apart from this, developed countries such as Dubai, Saudi Arabia, and Qatar have a big hand in the growth of the Middle East & Africa market.

 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America